AbbVie invests $195m to expand API manufacturing in the US
The pharma company will add to its existing Chicago site, boosting its active pharmaceutical ingredient production capacity.
List view / Grid view
The pharma company will add to its existing Chicago site, boosting its active pharmaceutical ingredient production capacity.
Sven Dethlefs will be tasked with driving its deupirfenidone programme in idiopathic pulmonary fibrosis.
The CDMO’s new site will support its work in cell and gene therapy.
Late-stage trials in Sjögren’s disease and primary immune thrombocytopenia met primary endpoints.
Amid intensifying market competition, the next-generation therapies could shape the future of oncology.
CBER head makes surprise comeback just weeks after his abrupt resignation.
The pharma company’s digital innovation efforts also progress with the opening of a new Hyderabad facility.
The scheme will provide more support and a streamlined application process to companies constructing new US facilities.
Amid shifting global dynamics, continued resilience in UK healthcare M&A deal activity is expected in H2 2025, forecasting predicts.
The European Commission hopes its planned legislation will enable biotechnology companies to bring products from laboratory to market more quickly.
Regulatory pressures and demand for trained operators is expected to hinder growth of the rapid microbiological testing market into the next decade, research suggests.
HHS throws out Pfizer, CSL Seqirus and Sanofi proposals, and will restructure AstraZeneca and Moderna projects.
The novel approach could reduce the industry’s reliance on fossil fuels by offering a sustainable production alternative for pharmaceuticals.
New digital initiative will support the pharma company’s manufacturing and supply chain ambitions.
The trial is the first pivotal clinical programme to have met the standard of complete scalp hair regrowth, suggesting potential in immune-mediated diseases.